Loading...
Market
Which genomic therapy will be the first to be selected based on genomic information within the gLHS network by the end of 2024?
2
National Institutes of Health•NIH•Vanderbilt University Medical Center•VUMC•Alex Bick•Sunil Kripalani•Dan Roden
Resolution / Starting Odds
Gene editing • 25%
RNA-based therapies • 25%
Cell therapy • 25%
Immunotherapy • 25%
Official reports from the gLHS network or NIH publications
Story
NIH Awards $27M to Establish Genomics-Enabled Learning Health Systems Network Across Six Sites, Including VUMC
Sep 23, 2024, 04:55 PM
The National Institutes of Health (NIH) has awarded $27 million to establish a new network of genomics-enabled learning health systems (gLHS). The network will consist of six sites, each proposing projects that use patient data to develop and refine aspects of genomic medicine. These projects will focus on implementing testing for hereditary diseases and selecting therapies based on genomic information. The initiative aims to analyze and improve how genomic information is integrated into patient care. Among the recipients, Vanderbilt University Medical Center (VUMC) will lead one of the clinical sites, with efforts spearheaded by Alex Bick, Sunil Kripalani, and Dan Roden.
View original story
Similar markets
NTLA-2002 • 25%
Editas Medicine Therapy • 25%
Beam Therapeutics Therapy • 25%
Other • 25%
Universal gene therapy • 33%
Mutation-specific gene therapy • 33%
No approval • 34%
Editas Medicine • 25%
Intellia Therapeutics • 25%
CRISPR Therapeutics • 25%
Other • 25%
Afami-cel • 25%
Cosibelimab • 25%
Adagrasib-Cetuximab • 25%
Other • 25%
ARO-DUX4 • 25%
ARO-MMP7 • 25%
Other program • 25%
No program reaches Phase 2 • 25%
Diabetes • 25%
Obesity • 25%
Heart Disease • 25%
Chronic Pain • 25%
Inflammatory Bowel Disease • 25%
Obesity • 25%
Diabetes • 25%
Other • 25%
Respiratory drug • 25%
Immunology drug • 25%
Vaccine • 25%
Other • 25%
Proof-of-concept data achieved • 25%
Partnership announcement • 25%
Regulatory approval submission • 25%
No major milestone achieved • 25%
Significant efficacy • 25%
Moderate efficacy • 25%
No efficacy • 25%
Inconclusive results • 25%
